Macular degeneration

Ophthotech Fovista AMD Phase 3 trials results come up short

Ophthotech Corporation has announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its Phase 3 clinical trial investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Eylea® (aflibercept) or Avastin® (bevacizumab) anti-VEGF therapy compared to Eylea or Avastin monotherapy for the treatment of

READ MORE…

Diabetic Retinopathy

Researchers identify new target for abnormal blood vessel growth in the eyes

A team led by Massachusetts Eye and Ear researchers has identified a novel therapeutic target for retinal neovascularization, or abnormal blood vessel growth in the retina, a hallmark of advanced diabetic eye disease. According to a report published online in Diabetes, the transcription factor RUNX1 was found in abnormal retinal blood vessels, and by inhibiting

READ MORE…

Macular edema on OCT

Eylea outperforms Avastin for DME in patients with moderate vision loss

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that visual improvement was greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision.  Gains after two years were about the same for Eylea and Lucentis

READ MORE…